SEVENTH AMENDMENT TO CREDIT AGREEMENT AND FIRST AMENDMENT TO PLEDGE AND SECURITY AGREEMENTPledge and Security Agreement • March 9th, 2017 • Recro Pharma, Inc. • Pharmaceutical preparations • New York
This SEVENTH AMENDMENT TO CREDIT AGREEMENT AND FIRST AMENDMENT TO PLEDGE AND SECURITY AGREEMENT (this “Amendment”) is made and entered into as of December 12, 2016 by and among RECRO GAINESVILLE LLC, a Massachusetts limited liability company (the “Borrower”), RECRO PHARMA, INC., a Pennsylvania corporation (“Parent”), RECRO ENTERPRISES, INC., a Delaware corporation (“Recro Enterprises”), RECRO IRELAND LIMITED, an Irish private company limited by shares (“Recro Ireland” and, together with Parent and Recro Enterprises, collectively, the “Grantors”) and ORBIMED ROYALTY OPPORTUNITIES II, LP, a Delaware limited partnership (together with its Affiliates, successors, transferees and assignees, the “Lender”).
SIXTH AMENDMENT TO CREDIT AGREEMENTCredit Agreement • March 9th, 2017 • Recro Pharma, Inc. • Pharmaceutical preparations • New York
This SIXTH AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of July 29, 2016 by and among RECRO GAINESVILLE LLC, a Delaware limited liability company (the “Borrower”) and ORBIMED ROYALTY OPPORTUNITIES II, LP, a Delaware limited partnership (together with its Affiliates, successors, transferees and assignees, the “Lender”).
First Amendment to Development, Manufacturing and Supply AgreementAnd Supply Agreement • March 9th, 2017 • Recro Pharma, Inc. • Pharmaceutical preparations
This First Amendment to Development, Manufacturing and Supply Agreement (this “Amendment”) is made and entered into as of October 19, 2016 by and between Alkermes Pharma Ireland Limited, a private limited company organized and existing under the laws of the Republic of Ireland (“Alkermes”), and Recro Pharma, Inc., a corporation organized and existing under the laws of Pennsylvania (“Recro”), Recro and Alkermes are sometimes hereinafter referred to each as a “Party” and collectively as the ‘Parties.”
FOURTH AMENDMENT TO CREDIT AGREEMENTCredit Agreement • March 9th, 2017 • Recro Pharma, Inc. • Pharmaceutical preparations • New York
This FOURTH AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of August 31, 2015 by and among RECRO PHARMA LLC, a Delaware limited liability company (the “Borrower”) and ORBIMED ROYALTY OPPORTUNITIES II, LP, a Delaware limited partnership (together with its Affiliates, successors, transferees and assignees, the “Lender”).
Second Amendment to Development, Manufacturing and Supply AgreementAnd Supply Agreement • March 9th, 2017 • Recro Pharma, Inc. • Pharmaceutical preparations
This Second Amendment to Development, Manufacturing and Supply Agreement (this “Second Amendment”) is made and entered into as of February 1, 2017 by and between Alkermes Pharma Ireland Limited, a private limited company organized and existing under the laws of the Republic of Ireland (“Alkermes”), and Recro Pharma, Inc., a corporation organized and existing under the laws of Pennsylvania (“Recro”). Recro and Alkermes are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties.”
SECOND AMENDMENT TO CREDIT AGREEMENTCredit Agreement • March 9th, 2017 • Recro Pharma, Inc. • Pharmaceutical preparations • New York
This SECOND AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of April , 2015 by and among RECRO PHARMA LLC, a Delaware limited liability company (the “Borrower”) and ORBIMED ROYALTY OPPORTUNITIES II, LP, a Delaware limited partnership (together with its Affiliates, successors, transferees and assignees, the “Lender”).
THIRD AMENDMENT TO CREDIT AGREEMENTCredit Agreement • March 9th, 2017 • Recro Pharma, Inc. • Pharmaceutical preparations • New York
This THIRD AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of July 9, 2015 by and among RECRO PHARMA LLC, a Delaware limited liability company (the “Borrower”) and ORBIMED ROYALTY OPPORTUNITIES II, LP, a Delaware limited partnership (together with its Affiliates, successors, transferees and assignees, the “Lender”).
